Biomica CEO Set to Engage in Panel Discussion at 8th Annual European Microbiome Movement Summit
REHOVOT, Israel, Jan. 23, 2024 /PRNewswire/ — Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), announced its CEO, Dr. Elran Haber, will participate in the 8th Annual Microbiome Movement Drug Development Summit Europe in Barcelona, Spain, from January 30 to February 1, 2024.
Related news for (EVGN)
- Evogene Reports Second Quarter 2025 Financial Results
- Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases
- Evogene Announces Completion of Transaction for the Sale of Lavie Bio’s Activity to ICL
- Closing Bell Buzz: Small Caps, Big Moves
- Don’t Miss Out: MoBot’s Latest Stock Updates 06/10/25 07:00 AM
